# Study of SY-201 Ophthalmic Solution in Subjects With Dry Eye Disease

> **NCT05370495** · PHASE1,PHASE2 · COMPLETED · sponsor: **Seinda Pharmaceutical Guangzhou Corporation** · enrollment: 201 (actual)

## Conditions studied

- Dry Eye Disease

## Interventions

- **DRUG:** SY-201 Ophthalmic Solution 2.0%
- **DRUG:** SY-201 Ophthalmic Solution 1.0%
- **DRUG:** SY-201 Ophthalmic Solution 0.5%
- **DRUG:** SY-201 Ophthalmic Solution Vehicle

## Key facts

- **NCT ID:** NCT05370495
- **Lead sponsor:** Seinda Pharmaceutical Guangzhou Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-07-25
- **Primary completion:** 2023-03-24
- **Final completion:** 2023-03-24
- **Target enrollment:** 201 (ACTUAL)
- **Last updated:** 2024-11-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05370495

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05370495, "Study of SY-201 Ophthalmic Solution in Subjects With Dry Eye Disease". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05370495. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*